BTLA and PD-1 combined with radiotherapy for enhancing antitumor immune response in lung cancer via the regulation of memory B cells to promote T-cell infiltration [0.03%]
BTLA和PD-1与放疗联合通过调节记忆B细胞促进T细胞浸润来增强肺癌的抗肿瘤免疫反应
Yingying Zhang,Yang Li,Can Feng et al.
Yingying Zhang et al.
Background: Radiotherapy (RT) combined with immunotherapy targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) has become one of the most promising strategies for treating patients with ...
Dynamic changes in liver-to-spleen ratio: can it be a prognostic biomarker for chemo-immunotherapy in small cell lung cancer? [0.03%]
肝脾密度比值动态变化会是小细胞肺癌化疗免疫治疗的预后生物标志物吗？
Yi Ren,Weiwei Liu,Jie Lou et al.
Yi Ren et al.
Background: The liver-to-spleen ratio (LSR) is a non-invasive imaging biomarker used to assess non-alcoholic fatty liver disease (NAFLD). Given the potential link between the NAFLD-associated immune microenvironment and s...
3D computed tomography airway geometry for predicting bronchoscopic accessibility in peripheral pulmonary nodules: a prospective study [0.03%]
有关外周型肺结节支气管镜可及性的三维CT气道解剖预测价值的前瞻性研究
Byeong-Ho Jeong,Jonghoon Kim,Hwanho Cho et al.
Byeong-Ho Jeong et al.
Background: Bronchoscopic diagnosis of peripheral pulmonary nodules (PPNs) using radial probe endobronchial ultrasound (rEBUS) has been widely studied. However, the prospective utility of computed tomography (CT)-derived ...
Diagnostic accuracy and safety of 1.1-mm cryoprobe biopsy for peripheral pulmonary lesions with or without oversheath [0.03%]
1.1mm冻力探针有或无导管套管进行肺外周病变诊断的准确性与安全性研究
Geunin Lee,Mindong Sung,Hyeyung Hong et al.
Geunin Lee et al.
Background: Cryobiopsy using a 1.1-mm probe enables the acquisition of larger and better-preserved tissue specimens for peripheral pulmonary lesions (PPLs). However, the effects of oversheathed cryobiopsy on diagnostic pe...
Gut microbiome in advanced non-small cell lung cancer: effect of chemotherapy and impact on efficacy [0.03%]
晚期非小细胞肺癌患者化疗对肠道菌群的影响及机制研究
Narumol Trachu,Insee Sensorn,Khantong Khiewngam et al.
Narumol Trachu et al.
Background: While evidence linking the gut microbiome (GM) to cancer immunotherapy is growing, data regarding its role in chemotherapy remains limited. This study aims to investigate the effect of chemotherapy on GM compo...
Pulmonary ground-glass opacity associated with cystic airspace: clinicopathological features and aggressiveness [0.03%]
与囊性气腔相关的肺磨玻璃影的临床病理特征及侵袭性
Ziwen Yu,Jianfu Li,Hongsheng Deng et al.
Ziwen Yu et al.
Background: Pulmonary ground-glass opacity (GGO) is often considered to have inert biological behavior. However, whether the clinicopathological features and aggressiveness of GGO associated with cystic airspace (GGO-A) d...
Pleural effusion volume as a novel biomarker for prognostic and therapeutic stratification in small cell lung cancer: a translationally-focused cohort study [0.03%]
小细胞肺癌预后及治疗分层的新生物标志物：胸腔积液量的队列研究
Wanjun Lu,Qiuxia Wu,Xin Liu et al.
Wanjun Lu et al.
Background: Malignant pleural effusion (MPE) in small cell lung cancer (SCLC) is uniformly classified as extensive-stage disease. However, the prognostic heterogeneity based on effusion volume remains uncharacterized, lea...
Justin M Bader,William de Santis,Emma Kane et al.
Justin M Bader et al.
Background: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell adhesion molecule implicated in tumor cell migration, invasion, and resistance to apoptosis. Its role as a circulating biomarker in...
Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer [0.03%]
用于预测晚期肺癌严重免疫检查点抑制剂相关心肌炎的列线图的开发和外部验证
Tao Luan,Kangjing Ma,Shuaiying Wang et al.
Tao Luan et al.
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced lung cancer, but immune checkpoint inhibitor-associated myocarditis (ICIM), particularly severe ICIM, remains a rare yet potentially fulmi...
Long-term outcomes of ALK inhibitors in metastatic ALK-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data [0.03%]
间变性淋巴瘤激酶阳性转移性非小细胞肺癌的ALK抑制剂长期疗效：基于重建患者水平数据的最新间接比较分析
Andrea Ossato,Vera Damuzzo,Luna Del Bono et al.
Andrea Ossato et al.
In metastatic ALK-positive non-small cell lung cancer (mNSCLC), ALK tyrosine kinase inhibitors (ALKi) represent the established standard of care. While second- and third-generation ALKi (including alectinib, brigatinib, ensartinib, envonalk...